Shanghai, China - MicroPort® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort® CardioFlow, stock code: 02160.HK) recently announced that following Alwide® Plus Balloon Catheter, the second generation of balloon catheter, Its self-developed new generation Transcatheter Aortic Valve Implantation (" TAVI ") product VitaFlow Liberty® Transcatheter Aortic Valve and Retrivable Delivery System (" VitaFlow Liberty® ") has received marketing approval from the Russian State Food and Drug Regulatory Agency (RZN).
VitaFlow Liberty® is the world’s only electric retrievable transcatheter aortic valve system, offering outstanding stability during procedure and hemodynamics post-procedure that will improve the quality of life for patients with aortic valve disease. It inherits the advantages of the VitaFlow® in terms of valve design, featuring a hybrid density self-expanding stent, bovine pericardial leaflets, and a high double-layer PET skirt design. This design offers robust radial force, improved coaxiality during deployment, and effectively reduces the incidence of perivalvular leakage post-procedure. Moreover, its breakthrough upgraded delivery system incorporates a unique and innovative double-reinforced spiral structure that ensures rapid, stable, and precise release and retrieval. This system also provides flexibility, allowing for 360-degree bending of the valve segment.
Previously, MicroPort® CardioFlow’s two generations of TAVI products, VitaFlow® and VitaFlow Liberty®, have fully covered more than 500 core hospitals in China and more than 80 core hospitals in overseas countries since their listing. The approval of VitaFlow Liberty® in Russia marked another important milestone for MicroPort® CardioFlow in the internationalization development , following Argentina, Colombia and Thailand. In the future, MicroPort® CardioFlow will continue to develop innovative technologies and launch more internationally competitive products to provide high-quality, universal total solutions for structural heart disease to more patients around the world.
©Copyright 1998-2023, MicroPort CardioFlow Medtech Corporation. All rights reserved. | 网站备案/许可证号:沪ICP备2023023560号 沪公网安备 31011502014876号
互联网药品信息服务资格证书编号:(沪)-非经营性 - 2024 - 0135
“MicroPort CardioFlow”及“ are registered trademarks of MicroPort CardioFlow Medtech Corporation.